

Special Issue

Recent Advances in Endocrine Disease and Atherosclerosis

Message from the Guest Editor

Atherosclerosis is one of the leading causes of death in the world. Many factors have been associated with the development of atherosclerosis and cardiovascular disease. Different endocrine disorders, such as diabetes, dyslipidemia, obesity, acromegaly, Cushing's syndrome, and hypothyroidism, have been associated with accelerated atherosclerosis and coronary artery disease. This Special Issue of *Biomedicines* focuses on recent advances in the etiology, pathogenesis, diagnosis, and treatment of endocrine disorders related to atherosclerosis and cardiovascular disease development. Detailed knowledge on this topic is needed to prevent the development of cardiovascular disease.

Guest Editor

Dr. Sergio Martínez-Hervás

1. Department of Medicine, University of Valencia and Endocrinology, 46010 Valencia, Spain
2. Nutrition Department, Hospital Clínico Universitario of Valencia, 46010 Valencia, Spain
3. INCLIVA Biomedical Research Institute, 46010 Valencia, Spain
4. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain

Deadline for manuscript submissions

31 March 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/200624

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).